AI in Precision Medicine Market Expands Genomic Capabilities With Tempus' US$600 Million Ambry Genetics Acquisition

Diagnostics and AI analytics converge as molecular testing opens opportunities for personalized care

Tempus AI completed its acquisition of Ambry Genetics on February 3, 2025, paying US$375 million in cash and US$225 million in shares. The US$600 million transaction brings genetic testing capabilities into a company focused on AI-enabled precision medicine and multimodal healthcare data. This combination strengthens the link between molecular diagnostics and patient-specific analysis, creating potential demand for genomic interpretation software, clinical data integration, and research services. It also raises competitive pressure on providers that lack connections between testing and analytical platforms.

Tempus AI, Illumina, NVIDIA, and Insilico Medicine participate across genomic analytics, computing infrastructure, and AI-driven therapeutic development. In April 2025, Illumina and Tempus announced a collaboration combining AI technologies with multimodal data to train genomic algorithms and generate evidence supporting molecular testing. Such partnerships create opportunities for sequencing suppliers, diagnostics developers, and software specialists to expand hospital and pharmaceutical relationships. Commercial differentiation increasingly depends on clinically useful insights, integration with existing workflows, and evidence that supports adoption beyond research settings.

Request Executive Sample: https://www.datamintelligence.com/download-sample/ai-in-precision-medicine-market?kailas

According to DataM Intelligence, the global AI in Precision Medicine Market was valued at US$2.76 billion in 2025 and is projected to reach US$25.46 billion by 2035, growing at a CAGR of 24.88% during 2026-2035. Genomic analysis, biomarker discovery, and individualized treatment planning underpin the forecast.

North America leads the market through pharmaceutical R&D, established diagnostics networks, and advanced digital healthcare infrastructure. Asia-Pacific is the fastest-growing region, supported by healthcare digitization and biomedical research investment. Oncology remains a major application because treatment selection relies heavily on molecular profiling and biomarker interpretation. Neurology applications are expanding, while multimodal analytics are attracting interest for their ability to connect genomic, imaging, and clinical information within patient-specific assessments.

Recent Development
May 2026: Tempus expanded its Bristol Myers Squibb collaboration across five oncology and neuroscience trial programs, using multimodal data to test trial assumptions and identify patient subgroups.

July 2026: Illumina added three companies, including Formation Bio, to its Billion Cell Atlas alliance. More than 350 million cells had been sequenced for model development.

July 2026: Tempus agreed to acquire Personalis for $16.25 per share, with an enterprise value of $1.5 billion. Closing remained pending in its quarterly disclosure.

August 2026: SOPHiA GENETICS partnered with AstraZeneca to develop two decentralized companion diagnostics covering solid tumors and hematological oncology.

August 2026: Tempus received FDA clearance for ECG-PH, software detecting signs associated with pulmonary hypertension in eligible symptomatic adults; it requires interpretation alongside other clinical information.

September 2026: Tempus and Recursion extended their data partnership through November 2029, replacing discretionary fees with $42 million in committed payments and adding an RNA foundation-model license.

Segmentation Analysis
Oncology demand increasingly centers on matching biomarkers with therapies and identifying residual disease. SOPHiA's AstraZeneca programs show how pharmaceutical launches can create demand for distributed laboratory analytics. Growth depends on validated assays, local implementation and regulatory clearance, making laboratory readiness commercially consequential.

Drug development applications monetize patient stratification and biological evidence. Tempus and Bristol Myers Squibb are testing control-group assumptions and identifying likely responders, while Illumina's perturbation datasets support target selection. These workflows attract buyers seeking better development decisions, although model outputs still require experimental and clinical validation.

Clinical decision software is extending beyond cancer into cardiopulmonary disease. ECG-PH uses existing recordings rather than requiring a new screening device. This creates an adoption route through workflows; eligibility restrictions, clinician interpretation, and follow-up capacity determine how effectively alerts translate into care.

Request a Customized Report According to Your Business Strategy: https://www.datamintelligence.com/customize/ai-in-precision-medicine-market?kailas

USA Market
The USA market is linking diagnostic operations with pharmaceutical data licensing. Tempus reported second-quarter 2026 diagnostics revenue of $289.3 million and Data and Applications revenue of $93.2 million. This combination illustrates two distinct purchasing channels: clinical testing and research intelligence.

Implementation remains a constraint. SOPHiA reported 80 customers signed to adopt its liquid biopsy application across more than 30 countries, with over half awaiting implementation. In the USA, its analysis volume increased 60%, supported by institutional deployments. Commercial assessment therefore needs to distinguish signed customers from laboratories actively generating reimbursable testing and analysis revenue.

Japan Market
Japan's opportunity includes pharmaceutical access to multimodal research data. In March 2026, SB TEMPUS began providing Chugai Pharmaceutical with de-identified Tempus genomic and clinical datasets for target discovery, resistance research and identifying underserved patient groups.

The disclosed library included over 8.5 million de-identified medical records and longitudinal mutation data covering over 1.5 million cancer patients. These are library-wide figures, not Japanese patient counts. For Japanese buyers, the opportunity is connecting research questions with molecular and treatment-outcome evidence. Local data acquisition and collaboration with healthcare institutions remain priorities, supporting demand for partnerships that combine analytics with clinical context.

Company Profiles
Tempus AI combines molecular diagnostics, clinical applications and data licensing. Quarterly revenue reached $382.5 million, up 22%. Lens supports pharmaceutical analytics; expanding testing strengthens its data ecosystem. The Personalis transaction adds integration and closing risks alongside residual-disease opportunities.

SOPHiA GENETICS provides cloud-based genomic and multimodal analysis through SOPHiA DDM. Quarterly revenue reached $23.3 million, up 27%, while net loss remained $22.4 million. Its decentralized network supports laboratory expansion, but implementation delays and country-specific approvals constrain conversion.

SB TEMPUS supplies genomic testing, healthcare data services and AI applications in Japan. Its Chugai relationship demonstrates pharmaceutical demand. Access to Tempus datasets supports research services, while clinical partnerships and representative Japanese data are essential for deployment.

Purchase This Exclusive Report: https://www.datamintelligence.com/buy-now-page?report=ai-in-precision-medicine-market?kailas

Additional Benefits:
✅ Get Interactive Dashboard Access (With No Additional Cost)
✅ Three months of analyst support to answer queries related to the report.

Contact Us:
Sai Kiran
Business Development Manager
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, Lalitha Nagar, Habsiguda,
Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com

About DataM Intelligence
DataM Intelligence is a global market research and business intelligence firm delivering actionable insights across healthcare, pharmaceuticals, chemicals, energy, technology, food, and industrial sectors. Through syndicated reports, custom research, consulting, and competitive intelligence services, the company helps organizations identify growth opportunities, navigate market challenges, and make informed strategic decisions in over 50+ countries worldwide.

This release was published on openPR.